The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NRSN | -20.48% | N/A | N/A | -77% |
| S&P | +13.95% | +78.35% | +12.25% | +49% |
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
No news articles found for NeuroSense Therapeutics.
| Q4 2024 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | $0.00K | 0.0% |
| Market Cap | $24.85M | 0.0% |
| Market Cap / Employee | $1.66M | 0.0% |
| Employees | 15 | 0.0% |
| Net Income | -$1,801.00K | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2024 | YOY Change | |
|---|---|---|
| Net Cash | $3.41M | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $73.00K | 0.0% |
| Q4 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -263.45% | 0.0% |
| Return On Invested Capital | -37.45% | 0.0% |
No data available for this period.
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -14.94 | -2.50 | -2.83 | -8.44 | - |
| Price to Tangible Book Value | -14.94 | -2.50 | -2.83 | -8.44 | - |
| Return on Equity | -2880.1% | - | |||
| Total Debt | $55.00K | $36.00K | $19.00K | $73.00K | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
